Back to results
US 2012/0071523 A1Published application
Benzofuran-4,5-diones as selective peptide deformylase inhibitors
AssigneeSloan-Kettering Institute for Cancer Research
InventorsHakim Djaballah, Christophe Antczak
Life of this patent
Estimating the term…
Abstract
The instant invention provides novel benzofuran-4,5-diones and pharmaceutical compositions thereof useful for inhibiting PDF and for treating proliferative and infectious diseases. Compounds may be selective for eukaryotic (e.g., human) PDF or prokaryotic PDF.
Claims35
A compound of the formula:
- wherein:
- R1 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORa;
- —C(═O)Ra;
- —CO2Ra;
- —CN;
- —SCN;
- —SRa;
- —SORa;
- —SO2Ra;
- —NO2;
- —N3;
- —N(Ra)2;
- —NRaC(═O)Ra;
- —NRaC(═O)N(Ra)2;
- —OC(═O)ORa;
- —OC(═O)Ra;
- —OC(═O)N(Ra)2;
- —NRaC(═O)ORa;
- or —C(Ra)3;
- wherein each occurrence of Ra is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- R2 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORb;
- —C(═O)Rb;
- —CO2Rb;
- —CN;
- —SCN;
- —SRb;
- —SORb;
- —SO2Rb;
- —NO2;
- —N3;
- —N(Rb)2;
- —NRbC(═O)Ra;
- —NRbC(═O)N(Rb)2;
- —OC(═O)ORb;
- —OC(═O)Rb;
- —OC(═O)N(Rb)2;
- —NRbC(═O)ORb;
- or —C(Rb)3;
- wherein each occurrence of Rb is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- wherein R1 and R2 when taken together form an optionally substituted, saturated or unsaturated aromatic, heteroaromatic, or nonaromatic 3-8 membered monocyclic or bicyclic ring optionally containing one or more heteroatoms selected from the group consisting of N, O, or S;
- R3 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORc;
- —C(═O)Rc;
- —CO2Rc;
- —CN;
- —SCN;
- —SRc;
- —SORc;
- —SO2Rc;
- —NO2;
- —N3;
- —N(Rc)2;
- —NRcC(═O)Rc;
- —NRcC(═O)N(Rc)2;
- —OC(═O)ORc;
- —OC(═O)Rc;
- —OC(═O)N(Rc)2;
- —NRcC(═O)ORc;
- or —C(Rc)3;
- wherein each occurrence of Rc is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- and
- R4 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORd;
- —C(═O)Rd;
- —CO2Rd;
- —CN;
- —SCN;
- —SRd;
- —SORd;
- —SO2Rd;
- —NO2;
- —N3;
- —N(Rd)2;
- —NRdC(═O)Rd;
- —NRdC(═O)N(Rd)2;
- —OC(═O)ORd;
- —OC(═O)Rd;
- —OC(═O)N(Rd)2;
- —NRdC(═O)ORd;
- or —C(Rd)3;
- wherein each occurrence of Rd is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety, or a pharmaceutically acceptable salt thereof;
- and
- wherein the compound is not of one of the formulae:
126 more elements
3-5. (canceled)
7-11. (canceled)
13-15. (canceled)
17-18. (canceled)
(canceled)
23-33. (canceled)
(canceled)
37-67. (canceled)
69-96. (canceled)
99-102. (canceled)
104-105. (canceled)
A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula:
- wherein:
- R1 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORa;
- —C(═O)Ra;
- —CO2Ra;
- —CN;
- —SCN;
- —SRa;
- —SORa;
- —SO2Ra;
- —NO2;
- —N3;
- —N(Ra)2;
- —NRaC(═O)Ra;
- —NRaC(═O)N(Ra)2;
- —OC(═O)ORa;
- —OC(═O)Ra;
- —OC(═O)N(Ra)2;
- —NRaC(═O)ORa;
- or —C(Ra)3;
- wherein each occurrence of Ra is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- R2 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORb;
- —C(═O)Rb;
- —CO2Rb;
- —CN;
- —SCN;
- —SRb;
- —SORb;
- —SO2Rb;
- —NO2;
- —N3;
- —N(Rb)2;
- —NRbC(═O)Ra;
- —NRbC(═O)N(Rb)2;
- —OC(═O)ORb;
- —OC(═O)Rb;
- —OC(═O)N(Rb)2;
- —NRbC(═O)ORb;
- or —C(Rb)3;
- wherein each occurrence of Rb is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- wherein R1 and R2 when taken together form an optionally substituted, saturated or unsaturated aromatic, heteroaromatic, or nonaromatic 3-8 membered monocyclic or bicyclic ring optionally containing one or more heteroatoms selected from the group consisting of N, O, or S;
- R3 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORc;
- —C(═O)Rc;
- —CO2Rc;
- —CN;
- —SCN;
- —SRc;
- —SORc;
- —SO2Rc;
- —NO2;
- —N3;
- —N(Rc)2;
- —NRcC(═O)Rc;
- —NRcC(═O)N(Rc)2;
- —OC(═O)ORc;
- —OC(═O)Rc;
- —OC(═O)N(Rc)2;
- —NRcC(═O)ORc;
- or —C(Rc)3;
- wherein each occurrence of Rc is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- and
- R4 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORd;
- —C(═O)Rd;
- —CO2Rd;
- —CN;
- —SCN;
- —SRd;
- —SORd;
- —SO2Rd;
- —NO2;
- —N3;
- —N(Rd)2;
- —NRdC(═O)Rd;
- —NRdC(═O)N(Rd)2;
- —OC(═O)ORd;
- —OC(═O)Rd;
- —OC(═O)N(Rd)2;
- —NRdC(═O)ORd;
- or —C(Rd)3;
- wherein each occurrence of Rd is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
124 more elements
A method for inhibiting PDF comprising contacting a cell with a compound of the formula:
- wherein:
- R1 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORa;
- —C(═O)Ra;
- —CO2Ra;
- —CN;
- —SCN;
- —SRa;
- —SORa;
- —SO2Ra;
- —NO2;
- —N3;
- —N(Ra)2;
- —NRaC(═O)Ra;
- —NRaC(═O)N(Ra)2;
- —OC(═O)ORa;
- —OC(═O)Ra;
- —OC(═O)N(Ra)2;
- —NRaC(═O)ORa;
- or —C(Ra)3;
- wherein each occurrence of Ra is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- R2 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORb;
- —C(═O)Rb;
- —CO2Rb;
- —CN;
- —SCN;
- —SRb;
- —SORb;
- —SO2Rb;
- —NO2;
- —N3;
- —N(Rb)2;
- —NRbC(═O)Ra;
- —NRbC(═O)N(Rb)2;
- —OC(═O)ORb;
- —OC(═O)Rb;
- —OC(═O)N(Rb)2;
- —NRbC(═O)ORb;
- or —C(Rb)3;
- wherein each occurrence of Rb is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- wherein R1 and R2 when taken together form an optionally substituted, saturated or unsaturated aromatic, heteroaromatic, or nonaromatic 3-8 membered monocyclic or bicyclic ring optionally containing one or more heteroatoms selected from the group consisting of N, O, or S;
- R3 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORc;
- —C(═O)Rc;
- —CO2Rc;
- —CN;
- —SCN;
- —SORc;
- —SO2Rc;
- —NO2;
- —N3;
- —N(Rc)2;
- —NRcC(═O)Rc;
- —NRcC(═O)N(Rc)2;
- —OC(═O)ORc;
- —OC(═O)Rc;
- —OC(═O)N(Rc)2;
- —NRcC(═O)ORc;
- or —C(Rc)3;
- wherein each occurrence of Rc is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- and
- R4 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORd;
- —C(═O)Rd;
- —CO2Rd;
- —CN;
- —SCN;
- —SRd;
- —SORd;
- —SO2Rd;
- —NO2;
- —N3;
- —N(Rd)2;
- —NRdC(═O)Rd;
- —NRdC(═O)N(Rd)2;
- —OC(═O)ORd;
- —OC(═O)Rd;
- —OC(═O)N(Rd)2;
- —NRdC(═O)ORd;
- or —C(Rd)3;
- wherein each occurrence of Rd is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety, or a pharmaceutically acceptable salt thereof, in an amount effective to inhibit PDF.
123 more elements
109-117. (canceled)
A method for inducing apoptosis comprising contacting a cell with a compound of the formula:
- wherein:
- R1 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORa;
- —C(═O)Ra;
- —CO2Ra;
- —CN;
- —SCN;
- —SRa;
- —SORa;
- —SO2Ra;
- —NO2;
- —N3;
- —N(Ra)2;
- —NRaC(═O)Ra;
- —NRaC(═O)N(Ra)2;
- —OC(═O)ORa;
- —OC(═O)Ra;
- —OC(═O)N(Ra)2;
- —NRaC(═O)ORa;
- or —C(Ra)3;
- wherein each occurrence of Ra is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- R2 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORb;
- —C(═O)Rb;
- —CO2Rb;
- —CN;
- —SCN;
- —SRb;
- —SORb;
- —SO2Rb;
- —NO2;
- —N3;
- —N(Rb)2;
- —NRbC(═O)Ra;
- —NRbC(═O)N(Rb)2;
- —OC(═O)ORb;
- —OC(═O)Rb;
- —OC(═O)N(Rb)2;
- —NRbC(═O)ORb;
- or —C(Rb)3;
- wherein each occurrence of Rb is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- wherein R1 and R2 when taken together form an optionally substituted, saturated or unsaturated aromatic, heteroaromatic, or nonaromatic 3-8 membered monocyclic or bicyclic ring optionally containing one or more heteroatoms selected from the group consisting of N, O, or S;
- R3 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORc;
- —C(═O)Rc;
- —CO2Rc;
- —CN;
- —SCN;
- —SRc;
- —SORc;
- —SO2Rc;
- —NO2;
- —N3;
- —N(Rc)2;
- —NRcC(═O)Rc;
- —NRcC(═O)N(Rc)2;
- —OC(═O)ORc;
- —OC(═O)Rc;
- —OC(═O)N(Rc)2;
- —NRcC(═O)ORc;
- or —C(Rc)3;
- wherein each occurrence of Rc is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- and
- R4 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORd;
- —C(═O)Rd;
- —CO2Rd;
- —CN;
- —SCN;
- —SRd;
- —SORd;
- —SO2Rd;
- —NO2;
- —N3;
- —N(Rd)2;
- —NRdC(═O)Rd;
- —NRdC(═O)N(Rd)2;
- —OC(═O)ORd;
- OC(═O)Rd;
- —OC(═O)N(Rd)2;
- —NRdC(═O)ORd;
- or —C(Rd)3;
- wherein each occurrence of Rd is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety, or a pharmaceutically acceptable salt thereof, in an amount effective to induce apoptosis.
124 more elements
119-135. (canceled)
A method for treating a proliferative disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula:
- wherein:
- R1 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORa;
- —C(═O)Ra;
- —CO2Ra;
- —CN;
- —SCN;
- —SRa;
- —SORa;
- —SO2Ra;
- —NO2;
- —N3;
- —N(Ra)2;
- —NRaC(═O)Ra;
- —NRaC(═O)N(Ra)2;
- —OC(═O)ORa;
- —OC(═O)Ra;
- —OC(═O)N(Ra)2;
- —NRaC(═O)ORa;
- or —C(Ra)3;
- wherein each occurrence of Ra is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- R2 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORb;
- —C(═O)Rb;
- —CO2Rb;
- —CN;
- —SCN;
- —SRb;
- —SORb;
- —SO2Rb;
- —NO2;
- —N3;
- —N(Rb)2;
- —NRbC(═O)Ra;
- —NRbC(═O)N(Rb)2;
- —OC(═O)ORb;
- —OC(═O)Rb;
- —OC(═O)N(Rb)2;
- —NRbC(═O)ORb;
- or —C(Rb)3;
- wherein each occurrence of Rb is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- wherein R1 and R2 when taken together form an optionally substituted, saturated or unsaturated aromatic, heteroaromatic, or nonaromatic 3-8 membered monocyclic or bicyclic ring optionally containing one or more heteroatoms selected from the group consisting of N, O, or S;
- R3 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORc;
- —C(═O)Rc;
- —CO2Rc;
- —CN;
- —SCN;
- —SRc;
- —SORc;
- —SO2Rc;
- —NO2;
- —N3;
- —N(Rc)2;
- —NRcC(═O)Rc;
- —NRcC(═O)N(Rc)2;
- —OC(═O)ORc;
- —OC(═O)Rc;
- —OC(═O)N(Rc)2;
- —NRcC(═O)ORc;
- or —C(Rc)3;
- wherein each occurrence of Rc is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- and
- R4 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORd;
- —C(═O)Rd;
- —CO2Rd;
- —CN;
- —SCN;
- —SRd;
- —SORd;
- —SO2Rd;
- —NO2;
- —N3;
- —N(Rd)2;
- —NRdC(═O)Rd;
- —NRdC(═O)N(Rd)2;
- —OC(═O)ORd;
- —OC(═O)Rd;
- —OC(═O)N(Rd)2;
- —NRdC(═O)ORd;
- or —C(Rd)3;
- wherein each occurrence of Rd is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety, or a pharmaceutically acceptable salt thereof.
124 more elements
137-163. (canceled)
A method for treating an infectious disease comprising contacting a cell with a therapeutically effective amount of a compound of the formula:
- wherein:
- R1 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORa;
- —C(═O)Ra;
- —CO2Ra;
- —CN;
- —SCN;
- —SRa;
- —SORa;
- —SO2Ra;
- —NO2;
- —N3;
- —N(Ra)2;
- —NRaC(═O)Ra;
- —NRaC(═O)N(Ra)2;
- —OC(═O)ORa;
- —OC(═O)Ra;
- —OC(═O)N(Ra)2;
- —NRaC(═O)ORa;
- or —C(Ra)3;
- wherein each occurrence of Ra is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- R2 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORb;
- —C(═O)Rb;
- —CO2Rb;
- —CN;
- —SCN;
- —SRb;
- —SORb;
- —SO2Rb;
- —NO2;
- —N3;
- —N(Rb)2;
- —NRbC(═O)Ra;
- —NRbC(═O)N(Rb)2;
- —OC(═O)ORb;
- —OC(═O)Rb;
- —OC(═O)N(Rb)2;
- —NRbC(═O)ORb;
- or —C(Rb)3;
- wherein each occurrence of Rb is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- wherein R1 and R2 when taken together form an optionally substituted, saturated or unsaturated aromatic, heteroaromatic, or nonaromatic 3-8 membered monocyclic or bicyclic ring optionally containing one or more heteroatoms selected from the group consisting of N, O, or S;
- R3 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORc;
- —C(═O)Rc;
- —CO2Rc;
- —CN;
- —SCN;
- —SRc;
- —SORc;
- —SO2Rc;
- —NO2;
- —N3;
- —N(Rc)2;
- —NRcC(═O)Rc;
- —NRcC(═O)N(Rc)2;
- —OC(═O)ORc;
- —OC(═O)Rc;
- —OC(═O)N(Rc)2;
- —NRcC(═O)ORc;
- or —C(Rc)3;
- wherein each occurrence of Rc is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety;
- and
- R4 is hydrogen;
- halogen;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
- cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic;
- substituted or unsubstituted, branched or unbranched acyl;
- substituted or unsubstituted aryl;
- substituted or unsubstituted heteroaryl;
- —ORd;
- —C(═O)Rd;
- —CO2Rd;
- —CN;
- —SCN;
- —SRd;
- —SORd;
- —SO2Rd;
- —NO2;
- —N3;
- —N(Rd)2;
- —NRdC(═O)Rd;
- —NRdC(═O)N(Rd)2;
- —OC(═O)ORd;
- —OC(═O)Rd;
- —OC(═O)N(Rd)2;
- —NRdC(═O)ORd;
- or —C(Rd)3;
- wherein each occurrence of Rd is independently hydrogen;
- halogen;
- a protecting group;
- an optionally substituted aliphatic or heteroaliphatic moiety;
- an acyl moiety;
- or an optionally substituted aryl or heteroaryl moiety, or a pharmaceutically acceptable salt thereof, to treat the infectious disease.
124 more elements
165-187. (canceled)
Dependencies are inferred from the claim text.